Compare RYAM & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYAM | SGMT |
|---|---|---|
| Founded | 1926 | 2006 |
| Country | United States | United States |
| Employees | 2325 | N/A |
| Industry | Paper | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.4M | 676.3M |
| IPO Year | 2014 | 2021 |
| Metric | RYAM | SGMT |
|---|---|---|
| Price | $9.26 | $10.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $14.00 | ★ $26.13 |
| AVG Volume (30 Days) | 620.6K | ★ 846.6K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,466,397,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.38 | $4.50 |
| 52 Week High | $11.85 | $11.45 |
| Indicator | RYAM | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 64.87 | 61.41 |
| Support Level | $8.99 | $10.10 |
| Resistance Level | $9.38 | $11.30 |
| Average True Range (ATR) | 0.25 | 0.51 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 90.76 | 77.98 |
Rayonier Advanced Materials Inc engaged in the production and sale of high-purity cellulose and other cellulose-based materials derived from renewable wood fiber. The company operates through five segments: Cellulose Specialties, which produces purified cellulose used in products such as filters, pharmaceuticals, food additives and electronics; Biomaterials, which produces products including biofuels, lignosulfonates and other bio-based chemicals; Cellulose Commodities, which manufactures absorbent and viscose pulp used in textiles and hygiene products; Paperboard, which produces coated paperboard used for packaging and printing applications; and High-Yield Pulp, which produces pulp used in paperboard, packaging and printing paper products.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.